In the general population, there is extensive evidence that the reduction in the risk of CV events is proportional to the SBP reduction achieved, with the absolute bene ts being greater in those with higher baseline risk of CV disease, and with no differ- ence in proportional risk reductions across groups de ned according to higher or lower baseline SBP.102 106 The meta- analysis of 21 RCTs by Xie et al. concluded that the absolute bene ts of lowering SBP were greater and the number-needed-to-treat was smaller in trials where all enrolled patients had vascular disease, diabetes, or kidney In this meta-analysis, on-treatment BP averaged 133/76 mm Hg on intensive treatment and 140/81 mm Hg on less-intensive treatment. Outcomes in patients with and without albuminuria at baseline were not reported separately. SPRINT provides further evidence that intensive SBP lowering reduces CV events and death in those at high CV risk. 